We use cookies for a better user experience. Read our Privacy Policy

I Agree

Chronic Idiopathic Constipation Treatment Market

Chronic Idiopathic Constipation Treatment Market (Drug Class: Serotonin-4 [5-Ht4] Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants, and Others; Route of Administration: Oral and Rectal; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030(CIC) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 - 2030

Market Players Focus on Improving Existing Chronic Idiopathic Constipation Therapies

Chronic idiopathic constipation is a highly prevalent functional bowel disorder that affects millions of individuals worldwide. Some of the major factors that contribute to the burgeoning number of patients suffering from chronic idiopathic constipation include sedentary lifestyle, increasing usage of anti-inflammatory agents, and drastic decline in the intake of dietary fibers. Over the past few years, considerable efforts have been made to improve the management of chronic idiopathic constipation. In the current scenario, empiric therapy has garnered considerable attention from the stakeholders operating in the current chronic idiopathic constipation treatment market – a trend that is expected to continue during the forecast period.

Researchers involved in the current chronic idiopathic constipation treatment market landscape are also increasingly focusing on the development of customized treatment plans that offer multi-symptom relief. Efforts are being made to improve the efficacy of the current therapeutic agents due to which, a steady growth of the global chronic idiopathic constipation treatment market is anticipated in the upcoming years. A number of players involved in the current market for chronic idiopathic constipation treatment are focusing on gaining approval from the FDA for the newly developed drugs and treatments.

At the back of these factors, along with the augmenting demand for chronic idiopathic constipation treatment, the global chronic idiopathic constipation treatment market is expected to surpass the US$ 15.9 Bn mark by the end of 2030.

Request a sample to get extensive insights into the Chronic Idiopathic Constipation Treatment Market

Consistent Progress in Management of Chronic Idiopathic Constipation to Bolster Market Growth

In the initial stages, chronic idiopathic constipation treatment primarily included a blend of medication review, lifestyle modifications, and patient education. While prescription treatments are expected to witness considerable adoption worldwide, a number of non-prescription chronic idiopathic constipation treatments, including fiber supplementation, has garnered popularity. Moreover, research activities suggest that soluble fibers such as psyllium offer relief to patients suffering from chronic idiopathic constipation in comparison with insoluble fibers including bran. The increasing usage of soluble fibers has led to a noteworthy improvement in global symptoms and stool consistency due to which, the chronic idiopathic constipation treatment market is largely leaning toward the utilization of soluble fibers in the empiric fiber therapy. The rising usage of osmotic laxatives, stimulant laxative, and bulking laxatives is expected to contribute to the growth of the global chronic idiopathic constipation treatment market as the demand for non-prescription treatments continues to move in the upward trajectory.

While non-prescription treatments are gradually gaining worldwide adoption, the demand for prescription treatments is on the rise. However, players operating in the current chronic idiopathic constipation treatment market landscape are increasingly focusing on catering to the unmet needs with existing chronic idiopathic constipation treatment alternatives.

Unpredictability, poor symptom relief, bloating, and inability to enhance the quality of life of current treatments have compelled companies in the current market for chronic idiopathic constipation treatment to introduce better prescription agents and mechanisms. Some of the recently developed prescription agents that are gaining fast-paced adoption include prosecretory agents and a host of FDA approved products such as linaclotide.

To understand how our report can bring difference to your business strategy, Ask for a brochure

FDA Approval of New Drugs to Aid Market Growth

In the current scenario, manufacturers operating in the chronic idiopathic constipation treatment market are increasingly seeking the approval of the FDA for their newly developed drugs. Gaining the approval of the FDA is expected to remain one of the core areas of focus for the chronic idiopathic constipation drug manufacturers over the course of the forecast period. A number of drugs has received the green signal from the FDA in recent years.

In February 2020, the U.S. FDA approved an osmotic laxative developed by the Braintree Laboratories to treat chronic idiopathic constipation among adults. While attaining the FDA approval is expected to remain a top priority, market players are likely to increase the R&D spending on the development of new therapeutics and products.

Moderate Impact of COVID-19 Pandemic on Global Market

The onset of the COVID-19 pandemic is expected to have a moderate impact on the global chronic idiopathic constipation treatment market in 2020. The first quarter of 2020 witnessed steady ascension in the demand for chronic idiopathic constipation treatment worldwide. However, outbreak of the COVID-19 pandemic toward the end of the first quarter and stringent lockdown measures implemented by governments in the second and the third quarter of 2020 are expected to negatively affect the adoption of chronic idiopathic constipation treatment. However, the demand is set to witness considerable growth toward the end of 2020, as governments around the world continue to lift the lockdown measures in a phased manner.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Chronic Idiopathic Constipation Treatment Market

Analysts’ Viewpoint

The global chronic idiopathic constipation treatment market is expected to grow at a healthy CAGR of ~7% during the forecast period. The market growth can be primarily attributed to factors such as increasing prevalence of chronic idiopathic constipation among adults worldwide, high demand for improved chronic idiopathic constipation treatment and therapies to address unmet needs of existing treatments, and research and development activities. Market players should focus on the development of new prescription as well as non-prescription chronic idiopathic constipation treatments and continue to invest in R&D activities.

Chronic Idiopathic Constipation Treatment Market: Overview

  • According to Transparency Market Research’s latest report on the global chronic idiopathic constipation treatment market for the historical period 2018–2019 and forecast period 2020–20230, promising pipeline is anticipated to drive the global m chronic idiopathic constipation treatment market
  • Constipation is a highly common chronic gastrointestinal disorder. Chronic idiopathic constipation (CIC) is a health condition in which a patient experiences chronic symptoms of constipation. Changing dietary habits, i.e., reduction in fluid and fiber intake in diet, changes in water balance, and changes in contractility of the colon cause chronic idiopathic constipation.

Increase in Demand for CIC Treatment Products to Drive Chronic Idiopathic Constipation Treatment Market

  • Steady rise in prevalence of constipation across the global population is leading to high demand for newer therapeutics. This, in turn, is estimated to drive the market. Healthcare providers and patients both report unmet needs with current chronic idiopathic constipation treatment options.
  • Around 50% of patients with chronic idiopathic constipation report dissatisfaction with non-prescription laxatives due to unpredictability, bloating, poor symptom relief, or inability to improve quality of life. Alternative agents with novel mechanisms of action are being developed for the last 10 years in order to address these concerns.
  • Likewise, several of the available specialty drugs are intended for use in adolescents and adult patients. Surge in incidence of constipation among children is likely to present significant opportunities for key players and new entrants to develop and launch specialty constipation drugs for pediatric use.

Rise in Healthcare Spending and Improvements in Healthcare Infrastructure Propel Chronic Idiopathic Constipation Treatment Market

  • Increase in the number of patients with chronic idiopathic constipation boosts adoption of newer products. Patients are more aware and proactive about their health, and are willing to seek effective treatment. Hence, rise in healthcare spending on constipation is likely to boost the market.
  • An article published in the American Journal of Managed Care in 2007 stated that people in the U.S. spent more than US$ 800 million on laxatives. Chronic idiopathic constipation has a significant impact on the healthcare system, and it accounted for 3.92% of all ambulatory care visits in the U.S. in 2014.

High Cost to Hamper Chronic Idiopathic Constipation Treatment Market

  • Chronic idiopathic constipation continues to be associated with significant costs. It is like numerous other common conditions that contribute to greater morbidity and healthcare costs.
  • An article published in the American Journal of Managed Care stated that around 81% of cost of chronic idiopathic constipation treatment is associated with the use of medical services, including visits to prescribers and outpatient services. It is reported that pharmacy costs for chronic constipation patients with abdominal symptoms is 1.6 times higher than patients who did not have abdominal symptoms.
  • Cost of treatment is an important concern regarding the selection of treatment. Hence, higher cost associated with treatment hampers the market. For instance, the annual cost of treatment of chronic idiopathic constipation ranges from US$ 1,912 to US$ 7,522 per patient. In the U.S., direct medical cost of medical constipation is estimated at US$ 230 million per year.

Chronic Idiopathic Constipation Treatment Market: Competition Landscape

  • This report profiles major players operating in the global chronic idiopathic constipation treatment market based on various attributes and recent developments
  • The global chronic idiopathic constipation treatment market is highly fragmented with the presence of numerous global as well as regional players
  • Leading players operating in the global chronic idiopathic constipation treatment market include
    • Bayer AG
    • Allergan
    • Bausch Health
    • Sanofi
    • Takeda Pharmaceutical Company
    • SEBELA PHARMACEUTICALS
    • Ironwood Pharmaceuticals, Inc.
    • Albireo Pharma, Inc.
    • Sucampo Pharmaceuticals, Inc. (Mallinckrodt)
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

Chronic Idiopathic Constipation Treatment Market: Key Developments

  • Key players in the global chronic idiopathic constipation treatment market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are aimed at addressing unmet needs in the chronic idiopathic constipation treatment market, strengthening the product portfolio, and investing in research & development.
  • A few expansion strategies adopted by players operating in the global chronic idiopathic constipation treatment market are:
  • In April 2020, Ironwood Pharmaceuticals, Inc. announced that the USPTO (United States Patent and Trademark) issued Notices of Allowance for patent applications covering the formulation of the 72 mcg dose of LINZESS
  • In March 2020, SEBELA PHARMACEUTICALS received approval from the U.S. Food and Drug Administration for Pizensy (lactitol). This approval represents a step forward in the treatment options for CIC.
  •  In September 2019, Ironwood Pharmaceuticals, Inc. entered into an amended collaboration agreement with AstraZeneca for the development and commercialization of LINZESS, in China
  • In February 2018, Mallinckrodt acquired Sucampo. Sucampo's primary commercialized product was Amitiza, a leading global product in the branded constipation market
  • The report on the global chronic idiopathic constipation treatment market discussed individual strategies, followed by company profiles of manufacturers of chronic idiopathic constipation treatment products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global chronic idiopathic constipation treatment market.

Chronic Idiopathic Constipation Treatment Market – Segmentation

Drug Class

  • Serotonin-4 (5-Ht4) Receptor Agonist
    • Prucalopride
    • Others
  • Guanylate Cyclase-C Agonist
    • Plecanatide
    • Linaclotide     
  • Laxatives
    • Sodium Picosulphate
    • Polycarbophil
    • Others
  • Stimulants
    • Bisacodyl
    • Senokot
    • Others
  • Others

Route of Administration

  • Oral
  • Rectal

Distribution Channel

  • Hospital Pharmacies   
  • Retail Pharmacies       
  • Online Pharmacies     

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Chronic Idiopathic Constipation Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of chronic idiopathic constipation treatment market?

Chronic Idiopathic Constipation Treatment Market to surpass valuation of US$ 15.9 Bn by 2030

What is the anticipated CAGR of the chronic idiopathic constipation treatment market in the forecast period?

Chronic Idiopathic Constipation Treatment Market is projected to expand at a CAGR of ~7% from 2020 to 2030

What are the key driving factors for the growth of the chronic idiopathic constipation treatment market?

Chronic Idiopathic Constipation Treatment Market is driven by increase in R&D activities and expenditure on new products and therapeutics development

Which region is expected to project the highest market share in the global chronic idiopathic constipation treatment market?

North America accounted for major share of the global chronic idiopathic constipation treatment market and the trend is anticipated to continue during the forecast period

Who are the key players in the global chronic idiopathic constipation treatment market?

Key players in the global chronic idiopathic constipation treatment market include Bayer AG, Allergan, Bausch Health, Sanofi, Takeda Pharmaceutical Company

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Chronic Idiopathic Constipation Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, 2018–2030

5. Key Insights

    5.1. Pipeline Analysis

    5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    5.3. Diseases Prevalence by Global/Sub-region

    5.4. Key Developments

6. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        6.3.1. Serotonin-4 (5-Ht4) Receptor Agonist

            6.3.1.1. Prucalopride

            6.3.1.2. Others

        6.3.2. Guanylate Cyclase-C Agonist

            6.3.2.1. Plecanatide

            6.3.2.2. Linaclotide

        6.3.3. Laxatives

            6.3.3.1. Sodium Picosulphate

            6.3.3.2. Polycarbophil

            6.3.3.3. Others

        6.3.4. Stimulants

            6.3.4.1. Bisacodyl

            6.3.4.2. Senokot

            6.3.4.3. Others

        6.3.5. Others

    6.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class

7. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        7.3.1. Oral

        7.3.2. Rectal

    7.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration

8. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel

9. Global Chronic Idiopathic Constipation Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Chronic Idiopathic Constipation Treatment Market Attractiveness, by Region

10. North America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        10.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

            10.2.1.1. Prucalopride

            10.2.1.2. Others

        10.2.2. Guanylate Cyclase-C Agonist

            10.2.2.1. Plecanatide

            10.2.2.2. Linaclotide

        10.2.3. Laxatives

            10.2.3.1. Sodium Picosulphate

            10.2.3.2. Polycarbophil

            10.2.3.3. Others

        10.2.4. Stimulants

            10.2.4.1. Bisacodyl

            10.2.4.2. Senokot

            10.2.4.3. Others

        10.2.5. Others

    10.3. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        10.3.1. Oral

        10.3.2. Rectal

    10.4. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        11.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

            11.2.1.1. Prucalopride

            11.2.1.2. Others

        11.2.2. Guanylate Cyclase-C Agonist

            11.2.2.1. Plecanatide

            11.2.2.2. Linaclotide

        11.2.3. Laxatives

            11.2.3.1. Sodium Picosulphate

            11.2.3.2. Polycarbophil

            11.2.3.3. Others

        11.2.4. Stimulants

            11.2.4.1. Bisacodyl

            11.2.4.2. Senokot

            11.2.4.3. Others

        11.2.5. Others

    11.3. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        11.3.1. Oral

        11.3.2. Rectal

    11.4. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        12.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

            12.2.1.1. Prucalopride

            12.2.1.2. Others

        12.2.2. Guanylate Cyclase-C Agonist

            12.2.2.1. Plecanatide

            12.2.2.2. Linaclotide

        12.2.3. Laxatives

            12.2.3.1. Sodium Picosulphate

            12.2.3.2. Polycarbophil

            12.2.3.3. Others

        12.2.4. Stimulants

            12.2.4.1. Bisacodyl

            12.2.4.2. Senokot

            12.2.4.3. Others

        12.2.5. Others

    12.3. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        12.3.1. Oral

        12.3.2. Rectal

    12.4. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        13.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

            13.2.1.1. Prucalopride

            13.2.1.2. Others

        13.2.2. Guanylate Cyclase-C Agonist

            13.2.2.1. Plecanatide

            13.2.2.2. Linaclotide

        13.2.3. Laxatives

            13.2.3.1. Sodium Picosulphate

            13.2.3.2. Polycarbophil

            13.2.3.3. Others

        13.2.4. Stimulants

            13.2.4.1. Bisacodyl

            13.2.4.2. Senokot

            13.2.4.3. Others

        13.2.5. Others

    13.3. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        13.3.1. Oral

        13.3.2. Rectal

    13.4. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

        14.2.1. Serotonin-4 (5-Ht4) Receptor Agonist

            14.2.1.1. Prucalopride

            14.2.1.2. Others

        14.2.2. Guanylate Cyclase-C Agonist

            14.2.2.1. Plecanatide

            14.2.2.2. Linaclotide

        14.2.3. Laxatives

            14.2.3.1. Sodium Picosulphate

            14.2.3.2. Polycarbophil

            14.2.3.3. Others

        14.2.4. Stimulants

            14.2.4.1. Bisacodyl

            14.2.4.2. Senokot

            14.2.4.3. Others

        14.2.5. Others

    14.3. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

        14.3.1. Oral

        14.3.2. Rectal

    14.4. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis/Ranking By Company (2019)

    15.3. Company Profiles

        15.3.1. Bayer AG

            15.3.1.1. Company Overview

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Allergan

            15.3.2.1. Company Overview

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. Bausch Health

            15.3.3.1. Company Overview

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Sanofi

            15.3.4.1. Company Overview

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Takeda Pharmaceutical Company

            15.3.5.1. Company Overview

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. SEBELA PHARMACEUTICALS

            15.3.6.1. Company Overview

            15.3.6.2. Growth Strategies

            15.3.6.3. SWOT Analysis

        15.3.7. Ironwood Pharmaceuticals, Inc.

            15.3.7.1. Company Overview

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Albireo Pharma, Inc.

            15.3.8.1. Company Overview

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Sucampo Pharmaceuticals, Inc. (Mallinckrodt)

            15.3.9.1. Company Overview

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

            15.3.10.1. Company Overview

            15.3.10.2. Company Financials

            15.3.10.3. Growth Strategies

            15.3.10.4. SWOT Analysis

List of Tables

Table 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 02: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 03: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 04: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 05: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 06: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 07: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 09: North America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 10: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 11: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 12: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 13: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 14: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 15: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 16: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 17: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 18: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 19: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 20: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 21: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 22: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 23: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 24: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 25: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 26: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 27: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 28: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 29: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 30: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 31: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 32: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 33: Latin America Chronic Idiopathic Constipation Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 34: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 35: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 36: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 37: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 38: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 39: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 40: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

Table 41: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 42: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

Table 43: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Table 44: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Guanylate Cyclase-C Agonist, 2018–2030

Table 45: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Laxatives, 2018–2030

Table 46: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Stimulants, 2018–2030

Table 47: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 48: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

List of Figures

Figure 01: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Drug Class, 2019

Figure 03: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Route of Administration, 2019

Figure 04: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Distribution Channel, 2019

Figure 05: Global Chronic Idiopathic Constipation Treatment Market Value Share, by Region, 2019

Figure 06: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

Figure 07: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

Figure 08: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Serotonin-4 (5-Ht4) Receptor Agonist, 2018–2030

Figure 09: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Guanylate Cyclase-C Agonist, 2018–2030

Figure 10: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Laxatives, 2018–2030

Figure 11: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Stimulants, 2018–2030

Figure 12: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Others, 2018–2030

Figure 13: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Serotonin-4 (5-Ht4) Receptor Agonist, 2019 and 2030

Figure 14: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Serotonin-4 (5-Ht4) Receptor Agonist, 2020–2030

Figure 15: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Guanylate Cyclase-C Agonist, 2019 and 2030

Figure 16: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Guanylate Cyclase-C Agonist, 2020–2030

Figure 17: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Laxatives, 2019 and 2030

Figure 18: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Laxatives, 2020–2030

Figure 19: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Stimulants, 2019 and 2030

Figure 20: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Stimulants, 2020–2030

Figure 21: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 22: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 23: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Oral, 2018–2030

Figure 24: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Rectal, 2018–2030

Figure 25: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

Figure 26: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Figure 27: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Hospital Pharmacies, 2018–2030

Figure 28: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Retail Pharmacies, 2018–2030

Figure 29: Global Chronic Idiopathic Constipation Treatment Market Value (US$ Mn), by Online Pharmacies, 2018–2030

Figure 30: Global Chronic Idiopathic Constipation Treatment Market Value Share Analysis, by Region, 2019 and 2030

Figure 31: Global Chronic Idiopathic Constipation Treatment Market Attractiveness Analysis, by Region

Figure 32: North America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 33: North America Chronic Idiopathic Constipation Market Value Share (%), by Country, 2019 and 2030

Figure 34: North America Chronic Idiopathic Constipation Market Attractiveness, by Country, 2020–2030

Figure 35: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 36: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 37: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 38: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 39: North America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 40: North America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 41: Europe Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 42: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 43: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 44: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 45: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 46: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 47: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 48: Europe Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 49: Europe Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 50: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 51: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 52: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 53: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 54: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 55: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 56: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 57: Asia Pacific Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 58: Asia Pacific Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 59: Latin America Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 60: Latin America Chronic Idiopathic Constipation Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 61: Latin America Chronic Idiopathic Constipation Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 62: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 63: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 64: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 65: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 66: Latin America Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 67: Latin America Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Figure 68: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 69: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 70: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Country/Sub-region, 2020–2030

Figure 71: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Drug Class, 2019 and 2030

Figure 72: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Drug Class, 2020–2030

Figure 73: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 74: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Route of Administration, 2020–2030

Figure 75: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Value Share (%), by Distribution Channel, 2019 and 2030

Figure 76: Middle East & Africa Chronic Idiopathic Constipation Treatment Market Attractiveness, by Distribution Channel, 2020–2030

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

972

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved